◎ホスピーラが世界的な機器の退役・交換戦略を発表

AsiaNet 52885

共同JBN 0499 （2013.5.2）

【レークフォレスト（米イリノイ州）2013年5月1日PRN＝共同JBN】注射用医薬品と注入技術の世界で有力なプロバイダーであるホスピーラ（Hospira, Inc.）（NYSE:HSP）（http://www.hospira.com）は1日、世界的機器戦略の詳細を発表した。この計画は機器の質を向上させる努力を含め、機器改善の継続的前進をサポートしながら、顧客のニーズに対応する簡素化、近代化された機器ポートフォリオを確立し、同社を将来の革新と成長に向けて位置づけるものである。

ホスピーラのリチャード・デービーズ最高商業責任者は「拡大を続ける患者の安全性、臨床結果に対する健康管理の集中を考えると、機器事業はホスピーラの主要な戦略的成長推進力と思われ、われわれは現在と将来の投資を通じて主導的地位を持続することにコミットしている。簡素化、近代化されたポートフォリオによって複雑さを減らし、性能を向上させ、明日の次世代技術を開発しながら今日の顧客と規制当局の期待によりよく対応できる立場になる」と語っている。

ホスピーラの新たな機器戦略は最近完了した同社の注入ポンプの包括的機器検査（世界で57万5000台以上が設置されている）に基づいている。同社は新たな戦略を米食品医薬品局（FDA）など世界の規制当局に伝え、これら当局と歩調をそろえる努力をしている。

行動には退役・交換計画への投資、将来の製品発売と品質システムが含まれる。

　＊退役・交換計画：それほど堅牢でないか古いポンプ技術を市場から退役させ、顧客の交換計画を開始させることによって同社の努力に集中する。活動の大半は今後2、3年内に行われ、これには次のものが含まれる。

　　－Symbiq（商標）注入機器とより古い旧型のPlum（商標）ポンプの退役、これらの機器のPlum A+ポンプへの交換と現在開発の進んだ段階にあるPlumプラットフォームへの将来の技術革新

    －GemStar（商標）移動ポンプの退役と、規制上の許可があり次第、可能な市場（カナダ、欧州の一部の国など）と米国などでその他の市場におけるこれらの機器のSapphire（商標）ポンプへの交換（注1）

    －古い旧型のPCAポンプの退役とこれらの機器のLifeCarePCA（商標）またはSapphireポンプへの交換

ホスピーラは退役、交換期間中は関係するポンプへのサポートを続ける。

　＊将来の技術：注入システムを電子健康記録（EHR）と統合するI.V.臨床統合技術の有力プロバイダーとしての同社の地位を強めながら次世代ポンプ技術と開発への投資に集中する。

　＊品質システム：ホスピーラの世界的機器品質システムを強化し、変化する規制標準によりよく対応するための継続的改善を促進する行動に投資する。

デービーズ氏はこれに付け加えて「ホスピーラは患者にとってのわが社の機器の世界的な重要性をよく認識しており、このプロセス全体の円滑な移行を確実にするために顧客と緊密に協力する」と述べている。

実行のために見込まれる経費を含む世界的機器戦略に関する詳しい情報はホスピーラの2013年5月1日付けの8-K文書（http://www.hospirainvestor.com/phoenix.zhtml?c=175550&p=irol-sec）に含まれている。

▽ホスピーラ（Hospira）について

ホスピーラは注射用医薬品と注入技術の世界で有力なプロバイダーである。その幅広い統合されたポートフォリオを通じて、ホスピーラは健康管理コストを低減しながら患者とケア提供者の安全性を向上させることによって「Advance Wellness」（商標）を実現するユニークな立場にある。本社は米イリノイ州レークフォレスト、従業員は約1万6000人。詳しい情報はhttp://www.hospira.comへ。

（注1）ホスピーラはQ Core Medical, Ltd.との販売協定を通じてSapphireポンプを販売している。

ソース：Hospira, Inc.

▽問い合わせ先

Media, Stacey Eisen, (224) 212-2276, or Tareta Adams, (224) 212-2535,

or Financial Community, Karen King (224) 212-2711,

or Ruth Venning, (224) 212-2774

Hospira Unveils Global Device Strategy

PR52885

LAKE FOREST, Ill., May 1, 2013 /PRN=KYODO JBN/ --

-- Takes customer-focused measures to streamline and modernize installed base

while enhancing the robustness of device portfolio --

Hospira, Inc. (NYSE: HSP) (http://www.hospira.com), the world's leading

provider of injectable drugs and infusion technologies, today unveiled details

of its global device strategy. The initiative establishes a streamlined and

modernized device portfolio to address customer needs and position the company

for future innovation and growth, while supporting continued advancement of

device remediation, including device quality improvement efforts.

"Given the ever-expanding focus in healthcare on improving patient safety and

clinical outcomes, we see our device business as a major strategic growth

driver for Hospira and are committed to sustaining our leadership position

through current and future investments," said Richard Davies, chief commercial

officer, Hospira. "With a streamlined and modernized portfolio, we will reduce

complexity, improve performance and be better positioned to meet the

expectations of customers and regulatory agencies today, while developing

tomorrow's next-generation technologies."

Hospira's new device strategy builds on the company's recently completed

comprehensive device review of its global installed base of more than 575,000

infusion pumps. The company communicated the new strategy to the U.S. Food and

Drug Administration (FDA) and other global regulatory agencies, and is working

with these agencies to gain alignment.

Actions will include investments in retirement and replacement programs, future

product releases and quality systems:

    - Retirement and replacement programs: Focus the company's efforts by

      retiring less robust and/or older pump technology from the market and

      initiating customer replacement programs. The majority of the activity

      will occur during the next two to three years and include:

        - retirement of the Symbiq(TM) infusion device and older legacy

          Plum(TM) pumps, replacing these devices with Plum A+ pumps and future

          innovations to the Plum platform currently under an advanced stage of

          development;

        - retirement of GemStar(TM) ambulatory pumps, replacing these devices

          with Sapphire(TM) pumps in markets where the device is available --

          such as Canada and certain countries in Europe -- and in the United

          States and other markets upon regulatory clearance;(1) and

        - retirement of older legacy PCA pumps, replacing these devices with

          LifeCare PCA(TM) or Sapphire pumps.

Hospira will continue to support the affected pumps during the retirement and

replacement period.

    - Future technology: Focus on investment in and development of next-

      generation pump technology while furthering the company's position as the

      leading provider of I.V. clinical integration technology, which

      integrates infusion systems with electronic health records (EHRs).

    - Quality systems: Invest in actions to strengthen Hospira's global device

      quality systems and promote continuous improvement to better meet

      evolving regulatory standards.

Added Mr. Davies, "Hospira is acutely aware of the importance of our devices

globally to the patients we serve, and we will work closely with our customers

to ensure a seamless transition throughout this process."

Additional information regarding the global device strategy, including the

expected charges of implementation, is included in Hospira's May 1, 2013, Form

8-K filing (http://www.hospirainvestor.com/phoenix.zhtml?c=175550&p=irol-sec).

About Hospira

Hospira, Inc. is the world's leading provider of injectable drugs and infusion

technologies. Through its broad, integrated portfolio, Hospira is uniquely

positioned to Advance Wellness(TM) by improving patient and caregiver safety

while reducing healthcare costs. The company is headquartered in Lake Forest,

Ill., and has approximately 16,000 employees. Learn more at

http://www.hospira.com.

Private Securities Litigation Reform Act of 1995 --

A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of

the Private Securities Litigation Reform Act of 1995, including statements

regarding Hospira's goals, plans and strategy related to Hospira's global

devices. Hospira cautions that these forward-looking statements are subject to

risks and uncertainties, including adequate and sustained progress on the

company's quality initiatives and device strategy that may cause actual results

to differ materially from those indicated in the forward-looking statements.

Economic, competitive, governmental, regulatory, legal, technological,

manufacturing supply, quality, modernizing and streamlining activities, and

other factors that may affect Hospira's operations and may cause actual results

to be materially different from expectations include the risks, uncertainties

and factors discussed under the headings "Risk Factors" and "Management's

Discussion and Analysis of Financial Condition and Results of Operations" in

Hospira's latest Annual Report on Form 10-K and subsequent Forms 10-Q, filed

with the Securities and Exchange Commission, which are incorporated by

reference. Hospira undertakes no obligation to release publicly any revisions

to forward-looking statements as the result of subsequent events or

developments.

(1) Hospira markets and distributes the Sapphire pump through a distribution

agreement with Q Core Medical, Ltd.

SOURCE: Hospira, Inc.

CONTACT: Media, Stacey Eisen, (224) 212-2276, or Tareta Adams, (224) 212-2535,

or Financial Community, Karen King (224) 212-2711, or Ruth Venning, (224)

212-2774